These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


1293 related items for PubMed ID: 19264687

  • 1. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
    Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM.
    N Engl J Med; 2009 Mar 05; 360(10):985-93. PubMed ID: 19264687
    [Abstract] [Full Text] [Related]

  • 2. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.
    Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, Robinson D, Wenzel S, Busse W, Hansel TT, Barnes NC, International Mepolizumab Study Group.
    Am J Respir Crit Care Med; 2007 Dec 01; 176(11):1062-71. PubMed ID: 17872493
    [Abstract] [Full Text] [Related]

  • 3. Effects of oral prednisone on sputum eosinophils and cytokines in patients with severe refractory asthma.
    Dente FL, Bacci E, Bartoli ML, Cianchetti S, Costa F, Di Franco A, Malagrinò L, Vagaggini B, Paggiaro P.
    Ann Allergy Asthma Immunol; 2010 Jun 01; 104(6):464-70. PubMed ID: 20568377
    [Abstract] [Full Text] [Related]

  • 4. Mepolizumab and exacerbations of refractory eosinophilic asthma.
    Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID.
    N Engl J Med; 2009 Mar 05; 360(10):973-84. PubMed ID: 19264686
    [Abstract] [Full Text] [Related]

  • 5. Inhaled fluticasone propionate is effective as well as oral prednisone in reducing sputum eosinophilia during exacerbations of asthma which do not require hospitalization.
    Di Franco A, Bacci E, Bartoli ML, Cianchetti S, Dente FL, Taccola M, Vagaggini B, Zingoni M, Paggiaro PL.
    Pulm Pharmacol Ther; 2006 Mar 05; 19(5):353-60. PubMed ID: 16289980
    [Abstract] [Full Text] [Related]

  • 6. Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations.
    Belda J, Margarit G, Martínez C, Bellido-Casado J, Casan P, Torrejón M, Brufal M, Rodríguez-Jerez F, Sanchis J.
    Eur Respir J; 2007 Dec 05; 30(6):1143-9. PubMed ID: 17690122
    [Abstract] [Full Text] [Related]

  • 7. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
    Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ, Mepolizumab HES Study Group.
    N Engl J Med; 2008 Mar 20; 358(12):1215-28. PubMed ID: 18344568
    [Abstract] [Full Text] [Related]

  • 8. Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma.
    Jayaram L, Duong M, Pizzichini MM, Pizzichini E, Kamada D, Efthimiadis A, Hargreave FE.
    Eur Respir J; 2005 Jan 20; 25(1):41-6. PubMed ID: 15640321
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
    Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE, Eustis S, Schwartz LW, Tsui P, Appelbaum ER, Martin EC, Bugelski PJ, Herzyk DJ.
    J Allergy Clin Immunol; 2001 Aug 20; 108(2):250-7. PubMed ID: 11496242
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008 Aug 20; 9(2):125-30. PubMed ID: 18298130
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.
    Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, Beglinger C, Smith DA, Patel J, Byrne M, Simon HU.
    Gut; 2010 Jan 20; 59(1):21-30. PubMed ID: 19828470
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.
    Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, Hijnen DJ, Plötz S, Knol EF, Kapp A, Bruijnzeel-Koomen CA, Ring J, de Bruin-Weller MS.
    Allergy; 2005 May 20; 60(5):693-6. PubMed ID: 15813818
    [Abstract] [Full Text] [Related]

  • 19. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
    Schwartz LB, Sheikh J, Singh A.
    Curr Med Res Opin; 2010 Aug 20; 26(8):1933-46. PubMed ID: 20565230
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 65.